Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?

American Journal of Clinical Pathology

Volumn 135, Issue 1, 2011, Pages 173-174

  Marinelli, Marilisa ^a   Raponi, Sara ^a   Del Giudice, Ilaria ^a   De Propris, Maria Stefania ^a   Nanni, Mauro ^a   Intoppa, Stefania ^a   Milani, Maria Laura ^a   Mauro, Francesca Romana ^a   Guarini, Anna ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

BONE MARROW BIOPSY; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LETTER; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY; SCREENING; SENSITIVITY AND SPECIFICITY;

BONE MARROW CELLS; CELL NUCLEUS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DIAGNOSTIC ERRORS; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79251504278     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPFMV43IFPRTWK     Document Type: Letter

References (14)

1. Chang H, Jiang AM, Qi CX. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia. Am J Clin Pathol. 2010;133:70-74.
2. Donher H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916. (Pubitemid 32064784)
3. Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322-3329.
4. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15:995-1004.
5. Lepelley P, Preudhomme C, Vanrumbeke M, et al. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia. 1994;8:1342-1349. (Pubitemid 24262491)
6. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91:4342-4349. (Pubitemid 28261999)
7. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-1184.
8. Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416. (Pubitemid 34864299)
9. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
10. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12-17. (Pubitemid 44921829)
11. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991;88:5413-5417.
12. Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood. 2003;102:1035-1041.
13. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
14. Zenz T, Benner A, Döhner H, et al. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle. 2008;7:3810-3814.